Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Robert Lawatscheck"'
Autor:
John M. Flack, Rajiv Agarwal, Stefan D. Anker, Bertram Pitt, Luis M. Ruilope, Peter Rossing, Sharon G. Adler, Linda Fried, Kenneth Jamerson, Robert Toto, Meike Brinker, Alfredo E. Farjat, Peter Kolkhof, Robert Lawatscheck, Amer Joseph, George L. Bakris
Publikováno v:
Kidney Medicine, Vol 5, Iss 12, Pp 100730- (2023)
Rationale & Objective: In FIDELITY, finerenone improved cardiorenal outcomes in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D). This analysis explored the efficacy and safety of finerenone in Black patients. Study Design: Subana
Externí odkaz:
https://doaj.org/article/59115e7a11df4a8396c5090a6e79d0dd
Autor:
Sylvia E. Rosas, Luis M. Ruilope, Stefan D. Anker, Bertram Pitt, Peter Rossing, Andres Angelo Cadena Bonfanti, Ricardo Correa-Rotter, Fernando González, Carlos Francisco Jaramillo Munoz, Pablo Pergola, Guillermo E. Umpierrez, Andrea Scalise, Charlie Scott, Robert Lawatscheck, Amer Joseph, George L. Bakris
Publikováno v:
Kidney Medicine, Vol 5, Iss 10, Pp 100704- (2023)
Rationale & Objective: In FIDELITY, finerenone improved cardiorenal outcomes in patients with chronic kidney disease (CKD) and type 2 diabetes. This analysis explores the efficacy and safety of finerenone in Hispanic patients. Study Design: Post hoc
Externí odkaz:
https://doaj.org/article/38abc2dc58b54b729cd012f48348caf8
Publikováno v:
International Journal of Molecular Sciences, Vol 23, Iss 16, p 9243 (2022)
Perception of the role of the aldosterone/mineralocorticoid receptor (MR) ensemble has been extended from a previously renal epithelial-centered focus on sodium and volume homeostasis to an understanding of their role as systemic modulators of reacti
Externí odkaz:
https://doaj.org/article/c0a72fa7b152452db8bdfca3fffc6387
Publikováno v:
BMJ Open, Vol 9, Iss 8 (2019)
ObjectiveTo investigate, in a simulator-based prospective study, whether telemedical support improves quality of emergency first response (performance) by medical non-professionals to being non-inferior to medical professionals.SettingIn a simulated
Externí odkaz:
https://doaj.org/article/664f208dc6c547d7b01ec3cc81659e73
Autor:
Rajiv Agarwal, Bertram Pitt, Biff F Palmer, Csaba P Kovesdy, Ellen Burgess, Gerasimos Filippatos, Jolanta Małyszko, Luis M Ruilope, Patrick Rossignol, Peter Rossing, Roberto Pecoits-Filho, Stefan D Anker, Amer Joseph, Robert Lawatscheck, Daniel Wilson, Martin Gebel, George L Bakris
Publikováno v:
Clinical Kidney Journal. 16:293-302
Background Mineralocorticoid receptor antagonists (MRAs) reduce systolic blood pressure (SBP) and increase serum potassium concentration ([K+]). This indirect comparison investigated any differences in SBP-lowering and hyperkalemia risk between finer
Autor:
Daniel Wilson, Peter Rossing, Amer Joseph, Peter Kolkhof, Charlie Scott, Luis M. Ruilope, Stefan D. Anker, Bertram Pitt, Robert Lawatscheck, George L. Bakris, Rajiv Agarwal, Gerasimos Filippatos
Publikováno v:
J Am Soc Nephrol
ABACUS. Repositorio de Producción Científica
Universidad Europea (UEM)
ABACUS. Repositorio de Producción Científica
Universidad Europea (UEM)
Background: Finerenone reduced risk of cardiorenal outcomes in patients with CKD and type 2 diabetes in the FIDELIO-DKD trial. We report incidences and risk factors for hyperkalemia with finerenone and placebo in FIDELIO-DKD. Methods: This post hoc s
Autor:
null Janet B. McGill, null Rajiv Agarwal, null Stefan D. Anker, null George L. Bakris, null Gerasimos Filippatos, null Bertram Pitt, null Luis M. Ruilope, null Andreas L. Birkenfeld, null M. Luiza Caramori, null Meike Brinker, null Amer Joseph, null Andrea Lage, null Robert Lawatscheck, null Charlie Scott, null Peter Rossing, null the FIDELIO‐DKD and FIGARO‐DKD investigators
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::02b788d4b4d0001d4fcbb1fe5d8f173a
https://doi.org/10.1111/dom.14999/v2/response1
https://doi.org/10.1111/dom.14999/v2/response1
Autor:
George L. Bakris, Luis M. Ruilope, Stefan D. Anker, Gerasimos Filippatos, Bertram Pitt, Peter Rossing, Linda Fried, Prabir Roy-Chaudhury, Pantelis Sarafidis, Christiane Ahlers, Meike Brinker, Amer Joseph, Robert Lawatscheck, Rajiv Agarwal
Publikováno v:
Bakris, G L, Ruilope, L M, Anker, S D, Filippatos, G, Pitt, B, Rossing, P, Fried, L, Roy-Chaudhury, P, Sarafidis, P, Ahlers, C, Brinker, M, Joseph, A, Lawatscheck, R, Agarwal, R & FIDELIO-DKD and FIGARO-DKD Investigators 2023, ' A prespecified exploratory analysis from FIDELITY examined finerenone use and kidney outcomes in patients with chronic kidney disease and type 2 diabetes ', Kidney International, vol. 103, no. 1, pp. 196-206 . https://doi.org/10.1016/j.kint.2022.08.040
In FIDELITY, a prespecified pooled analysis of the FIDELIO-DKD and FIGARO-DKD studies, finerenone was found to improve cardiorenal outcomes in patients with type 2 diabetes, a urine albumin-to-creatinine ratio of 30–5000 mg/g, an estimated glomerul
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::efd3995a00e57d145aa7f85f02852a72
https://curis.ku.dk/ws/files/334305892/1_s2.0_S0085253822009103_main.pdf
https://curis.ku.dk/ws/files/334305892/1_s2.0_S0085253822009103_main.pdf
Autor:
Peter, Rossing, Rajiv, Agarwal, Stefan D, Anker, Gerasimos, Filippatos, Bertram, Pitt, Luis M, Ruilope, Vivian, Fonseca, Guillermo E, Umpierrez, Maria Luiza, Caramori, Amer, Joseph, Marc, Lambelet, Robert, Lawatscheck, George L, Bakris
Publikováno v:
the FIDELIO-DKD and FIGARO-DKD investigators 2023, ' Finerenone in patients across the spectrum of chronic kidney disease and type 2 diabetes by glucagon-like peptide-1 receptor agonist use ', Diabetes, Obesity and Metabolism, vol. 25, no. 2, pp. 407-416 . https://doi.org/10.1111/dom.14883
AimsTo explore the modifying effect of glucagon-like peptide-1 receptor agonist (GLP-1RA) use on outcomes with finerenone across a wide spectrum of patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) in the pooled analysis of FIDELIO
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eebcad350786a56f6cf8def242306db8
https://curis.ku.dk/ws/files/359728926/Diabetes_Obesity_Metabolism_2022_Rossing_Finerenone_in_patients_across_the_spectrum_of_chronic_kidney_disease_and.pdf
https://curis.ku.dk/ws/files/359728926/Diabetes_Obesity_Metabolism_2022_Rossing_Finerenone_in_patients_across_the_spectrum_of_chronic_kidney_disease_and.pdf
Autor:
null Peter Rossing, null Rajiv Agarwal, null Stefan D. Anker, null Gerasimos Filippatos, null Bertram Pitt, null Luis M. Ruilope, null Vivian Fonseca, null Guillermo E. Umpierrez, null Maria Luiza Caramori, null Amer Joseph, null Marc Lambelet, null Robert Lawatscheck, null George L. Bakris, null the FIDELIO‐DKD and FIGARO‐DKD Investigators
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::337e535a3d4c66097a32c6335a5f92c9
https://doi.org/10.1111/dom.14883/v2/response1
https://doi.org/10.1111/dom.14883/v2/response1